Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis

In this study, non-inferiority could n ot be declared for 37.5 or 25 mg DR following breakfast QM (p = 0.1346 orp = 0.6711, respectively) versus 2.5 mg IR on awakening QD.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research